Clinical TrialJul 1, 2026, 07:36 AM
PMGC's NorthStrive Biosciences Announces Positive Phase III Results
AI Summary
PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences Inc., announced positive results from Phase III of its AI-driven drug discovery program with Yuva Biosciences. The program, utilizing Yuva's MitoNova™ AI platform, identified four small-molecule candidates (C1, C2, C3, C4) that significantly increased ANT1 protein expression in primary human skeletal muscle cells. The strongest candidates demonstrated dose-dependent induction, with increases up to +50%. These findings support advancing the compounds for further confirmatory testing and development, focusing on muscle preservation and metabolic stress.
Key Highlights
- NorthStrive Biosciences announced positive Phase III results for its AI-driven drug discovery program.
- Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.
- C2 showed up to +50% ANT1 induction, C4 up to +48%, and C1 up to +46%.
- C3 demonstrated a +29% increase in ANT1 expression at the highest tested dose.
- The program aims to identify candidates for muscle preservation and metabolic stress.
- Results support advancing the four validated candidates for confirmatory testing and further development.
Price Impact
More from ELAB